Abstract: A combination of 2-acetoxy-5-(?-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, which possess excellent inhibitory activity against platelet aggregation and thrombogenesis, and is useful for preventing or treating diseases caused by thrombus or embolus.
Abstract: The present invention provides methods of carrying out the safe and reliable preparation of lipids comprising quaternary amines. Such lipids are especially suited for introducing therapeutic agents into cells or organisms. In particular, the lipids of the invention are suitable for the efficient transfer of gene therapy agents into mammalian cells or organisms in a cell type specific or tissue specific manner.
Abstract: This invention relates to a stable epoprostenol composition that can be combined with commercially available IV fluids and can be administered in its reconstituted and/or diluted form under ambient conditions of about 15-30° C. for greater than 24 hours. The composition preferably contains (a) epoprostenol or a salt thereof; (b) a alkalinization agent; and (c) a base, such that when reconstituted or in solution, the solution has a pH>11. Methods for making the lyophilized composition are also disclosed.
Abstract: The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.
Type:
Grant
Filed:
December 13, 2007
Date of Patent:
November 27, 2012
Assignee:
Sanofi
Inventors:
Bernard Abramovici, Jean-Claude Gautier, Jean-Claude Gromenil, Jean-Marie Marrier
Abstract: The use of dapsone is the first effective treatment against the disabling consequences associated with cerebral infarction in patients. Dapsone was evaluated as a neuroprotector in the cerebral infarction model produced by the occlusion of the middle cerebral artery in rats and in patients suffering from acute cerebral infarction caused by thromboembolism. In both studies, dapsone displayed a reduction of between 70 and 90% in the adverse effects which occur as a consequence of the infarction.
Type:
Grant
Filed:
March 16, 2004
Date of Patent:
September 18, 2012
Assignees:
Universidad Autonoma Metropolitana, Instituto Nacional de Neurologia y Neurocirurgia Manuel Velasco Suarez
Inventors:
Luis Camílo Ríos Castañeda, Marina Altagracia Martínez, Juan Nader Kawachi, Jaime Kravzov Jinich
Abstract: Disclosed is a method of enhancing the immune response of an animal, including mammals and humans, to prevent or ameliorate immunoinflammatory diseases such as Inflammatory Bowel Disease, increase immune system development, maintain or increase CD4+ and CD8+ T lymphocyte levels, increase immune function, increase immune response against viruses and prevent or ameliorate the Metabolic Syndrome, Type 2 diabetes and obesity by administering orally or parenterally a therapeutically effective amount of punicic acid to the animal.
Abstract: The subject invention provides materials and methods for improving alcohol metabolism in animals. In a preferred embodiment, the invention provides methods for increasing the ability of people to consume alcohol while reducing hangovers or other effects of intoxication. Specifically exemplified herein is the use of a cysteamine compound to reduce the adverse effects of alcohol consumption. For example, the undesirable and unpleasant symptoms association with hangovers can be reduced through consumption, according to the subject invention, of cysteamine hydrochloride.
Abstract: To perform large-scale multiplex analysis of lipid-specific binding, lipid microarrays were developed. Lipids identified as disease associated, or analogs there, can be tolerogenic to patients suffering from autoimmune disease. Lipid array analysis has revealed anti-lipid antibodies in patients with immune disorders, and may contribute to the pathogenesis of disease.
Type:
Grant
Filed:
July 21, 2006
Date of Patent:
August 28, 2012
Assignees:
The Board of Trustees of the Leland Stanford Junior University, U.S. Department of Veteran Affairs
Inventors:
Jennifer L. Kanter, William H. Robinson, Lawrence Steinman
Abstract: Disclosed are methods for treating a subject suffering from phenylketonuria and/or phenylalanemia. The methods include, in part, enterally administering to the subject a LNAA supplement in which the weight ratio of Leu to Val is greater than 2:1; in which the weight ratio of Leu to iLeu is greater than 3:1; or which includes one or more LNAAs and which further includes Lys. LNAA supplements are also disclosed. Also disclosed are methods for treating a subject suffering from a condition involving a metabolic disorder involving the metabolism of a first amino acid X. The method includes enterally administering to the subject a composition which (i) is substantially free from the first amino acid X and (ii) which includes a second amino acid Y that competes with amino acid X at a gastrointestinal tract transporter.
Abstract: The use of type V phosphodiesterase inhibitors as a novel independent therapeutic modality in the treatment of exercise induced pulmonary hemorrhage in equine is described. The type V phosphodiesterase inhibitor is injected into the horse intravenously as a stand-alone agent from about one-half hour to about seven (7) days prior to the onset of strenuous exercise.
Abstract: The present invention relates generally to formulations comprising paracetamol. More particularly, the present invention provides a swallow formulation comprising paracetamol which facilitates the rapid delivery of paracetamol into the circulatory system following oral administration. The present invention further relates to methods for inducing efficient pain relief including an analgesic effect by the administration of the paracetamol formulation.
Type:
Grant
Filed:
November 27, 2006
Date of Patent:
July 10, 2012
Assignee:
Imaginot Pty Ltd.
Inventors:
Michael Stephen Roberts, Ruoying Jiang, Keivan Bezanehtak, Greg Andrew Davey, George Alexander Davidson, Geraldine Ann Elliott, Stephen Douglas Chandler, Mantu Sarkar
Abstract: This invention provides organic/inorganic composite biomaterials constituted by composites of hydroxyapatite and collagen and having an average fiber length of 60 ?m or longer, and a process for producing the same in which the calcium ion and phosphate ion concentrations in the reaction vessel are optimized through regulation of the concentration of a starting material and the flow rate. The organic/inorganic composite biomaterials have mechanical strength and a biodegradation rate suitable for artificial bones through the introduction of crosslinking therein.
Abstract: The present invention provides oral pravastatin formulations comprising a physical mixture of pravastatin and at least one pharmaceutically-acceptable excipient, wherein the composition for at least 6 months after its preparation is stable and has a pH of greater than about 7 to less than 9, as well as methods for the preparation and use of these stable formulations.
Abstract: Methods for inhibiting a neoplasm in a subject and methods of inhibiting undesired angiogenesis that include administering to a subject a therapeutically effective amount of at least one novel tetrahalogenated compound, or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
October 10, 2008
Date of Patent:
March 27, 2012
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services
Inventors:
William D. Figg, Erin Gardner, Michael Gutschow, Agnieszka Ambrozak
Abstract: The present invention provides a method for treating peripheral vascular diseases in a mammalian subject, which comprises administering to the patient in need thereof an effective amount of 11-deoxy-prostaglandin compound.
Abstract: The present invention relates to a combination of organic compounds, a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of treatment or prevention of certain conditions or diseases.
Abstract: Provided herein are aminoquinolones and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating, preventing or ameliorating GSK-3 mediated diseases.
Type:
Grant
Filed:
March 13, 2007
Date of Patent:
November 22, 2011
Assignee:
Kyorin Pharmaceutical Co., Ltd.
Inventors:
Oana Cociorva, Bei Li, Anna Katrin Szardenings, Yasumichi Fukuda, Masahiro Nomura, Shigeki Seto, Kazuhiro Yumoto, Kyoko Okada, Ayako Nakamura
Abstract: Nicotine receptor agonists or analogs or derivatives thereof for treating inflammatory pulmonary diseases, and pharmaceutical compositions including nicotine receptor agonists or analogs or derivatives thereof. Compounds of formula wherein R1, R2, Xa and Ya are as defined herein are also provided.
Type:
Grant
Filed:
July 15, 2005
Date of Patent:
October 18, 2011
Assignee:
Universite Laval
Inventors:
Yvon Cormier, Evelyne Israel-Assayag, Marie-Renée Blanchet, René C. Gaudreault, Philippe Labrie
Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.
Type:
Grant
Filed:
September 17, 2004
Date of Patent:
July 5, 2011
Assignees:
The United States of America as represented by the Department of Health and Human Services, P2D Inc.
Inventors:
Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg
Abstract: The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.
Type:
Grant
Filed:
May 10, 2007
Date of Patent:
April 19, 2011
Assignee:
Janssen Pharmaceutica NV
Inventors:
Thomas Rano, Gee-Hong Kuo, Ellen Sieber-McMaster, Keith T. Demarest, Patricia Pelton, Aihua Wang